Published in Med Hypotheses on September 07, 2011
Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells. PLoS One (2013) 1.11
Long non-coding RNAs as surrogate indicators for chemical stress responses in human-induced pluripotent stem cells. PLoS One (2014) 0.95
Noncoding RNAs involved in mammary gland development and tumorigenesis: there's a long way to go. J Mammary Gland Biol Neoplasia (2012) 0.92
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell (2002) 5.58
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell (2009) 3.18
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med (2011) 2.25
Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol (2009) 2.14
Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol (2006) 1.93
E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res (2007) 1.70
Desmoplastic small round cell tumor of the lung. Arch Pathol Lab Med (2002) 1.65
ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol (2005) 1.55
Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum Mol Genet (2004) 1.46
Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn (2007) 1.31
Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets (2012) 1.27
LEDGF (p75) promotes DNA-end resection and homologous recombination. Nat Struct Mol Biol (2012) 1.27
Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res (2002) 1.25
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer (2004) 1.24
Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J (2005) 1.23
Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle (2009) 1.21
Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle (2006) 1.20
Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene (2002) 1.14
Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res (2004) 1.12
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol (2006) 1.10
IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal (2012) 1.09
Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res (2010) 1.08
Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol (2003) 1.07
Identification and quantification of newly synthesized proteins translationally regulated by YB-1 using a novel Click-SILAC approach. J Proteomics (2012) 1.06
ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res (2010) 1.02
Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. Hum Pathol (2003) 1.00
Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity. Mol Cell Biol (2004) 0.99
ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene (2002) 0.99
Ets-1 binds cooperatively to the palindromic Ets-binding sites in the p53 promoter. Biochem Biophys Res Commun (2008) 0.96
Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol (2003) 0.95
HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proc Natl Acad Sci U S A (2014) 0.94
Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers. Oncotarget (2013) 0.94
Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol (2007) 0.93
Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma. Oncologist (2010) 0.92
A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation. J Biol Chem (2003) 0.92
Small round cell sarcomas. Semin Oncol (2009) 0.92
Classification of malignant pediatric renal tumors by gene expression. Pediatr Blood Cancer (2006) 0.91
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Res (2007) 0.91
Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res (2011) 0.90
TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis. Apoptosis (2013) 0.89
The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor. Proc Natl Acad Sci U S A (2005) 0.87
On translational regulation and EMT. Semin Cancer Biol (2012) 0.86
Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J Pathol (2012) 0.85
Ubiquitous expression of the monomeric red fluorescent protein mCherry in transgenic mice. Genesis (2010) 0.84
Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformation. J Biol Chem (2013) 0.83
Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther (2010) 0.82
Cryptic t(X;18), ins(6;18), and SYT-SSX2 gene fusion in a case of intraneural monophasic synovial sarcoma. Cancer Genet Cytogenet (2002) 0.82
Sarcomas with spindle cell morphology. Semin Oncol (2009) 0.82
Characterization of NKIP: a novel, Na+/K+-ATPase interacting protein mediates neural differentiation and apoptosis. Exp Cell Res (2007) 0.75
ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. Br J Haematol (2002) 0.75
Caspase cleavage of Ets-1 p51 generates fragments with transcriptional dominant-negative function. Biochem J (2010) 0.75
Erratum: Long noncoding RNA: noncoding and not coded. Cell Death Discov (2017) 0.75